Last update:

Allergy and immunology news

A renewable cell source for cancer immunotherapy could make off-the-shelf treatments possible

In a paper published in Cell, a USC Stem Cell-led team reports a new way of generating a renewable and expandable supply of the progenitor cells that give rise to macrophages. These immune cells help drive the body's response ...

New tool maps how T cells move within tumors

Researchers at UT Southwestern Medical Center led a study to develop a computational method that reveals how immune cells navigate the complex environment inside tumors, offering insights that could inform future cancer therapies. ...

Teaching the immune system to fight aging

Maybe we shouldn't be surprised that so-called "zombie cells" come with a catch. In response to severe damage, when cells can't recover full function but aren't ready to die, they can become senescent, in a zombie-like state ...

Painless skin patch offers new way to monitor immune health

Researchers at The Jackson Laboratory (JAX), in collaboration with the Massachusetts Institute of Technology (MIT), have developed the first bandage-like microneedle patch that can sample the body's immune responses painlessly ...

Smart patch detects allergies before symptoms strike

A wearable device that alerts people with food allergies before a reaction begins has the potential to reduce life-threatening anaphylaxis and transform allergy management from reactive to preventive care. The AllergE patch ...

How a tick could help prevent diseases like MS and cancer

A team from the Monash University Biomedicine Discovery Institute has identified a tick-derived evasin that can bind to two major classes of chemokines, a discovery that is important for the development of therapeutics targeting ...

Paradigm shift in immune checkpoint biology

A research team led by Professor Ki-Young Lee at the College of Medicine, Sungkyunkwan University, has uncovered a previously unrecognized tumor-intrinsic role of the immune checkpoint molecule PD-L1, providing new mechanistic ...

FDA approves Dupixent for allergic fungal rhinosinusitis

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) and a history of sino-nasal surgery.